BioNumerik Enters Strategic Marketing Partnership

San Antonio, TX, October 8, 2004 – BioNumerik Pharmaceuticals Inc., a San Antonio, Texas-based drug company focused on cancer therapies and the prevention of side effects for existing cancer therapies, has entered into a strategic marketing partnership with Takeda Pharmaceutical Co. Ltd. As part of the deal, BioNumerik will receive a $52 million equity investment from Takeda. BioNumerik currently is in registration for an $86.25 million IPO, and has raised VC funding from investors like Woodside Fund, Access Venture Partners, Delta Capital Management, SBC Communications Inc., Southwest Venture Partnerships and Grelan Pharmaceutical Co. Ltd. (www.bionumerik.com)

For more information contact:
Don Mundie, Managing Partner
Delta Capital Management, LLC
901.755.0949